13G Filing: Armistice Capital and Novelion Therapeutics Inc. (NVLN)

Page 5 of 10

Page 5 of 10 – SEC Filing

CUSIP No
67001K202
Item 1.
(a).
Name of Issuer:
Novelion Therapeutics Inc.
(b).
Address of Issuer’s Principal Executive Offices:
887 Great Northern Way, Suite 250
Vancouver, B.C.
Canada
Item 2.
(a).
Name of Person Filing:
Armistice Capital, LLC
Armistice Capital Master Fund Ltd.
Steven Boyd
(b).
Address of Principal Business Office, or if None, Residence:
Armistice Capital, LLC
510 Madison Avenue, 22nd Floor
New York, New York 10022
United States of America
Armistice Capital Master Fund Ltd.
c/o dms Corporate Services Ltd.
20 Genesis Close
P.O. Box 314
Grand Cayman KY1-1104
Cayman Islands
Steven Boyd
c/o Armistice Capital, LLC
510 Madison Avenue, 22nd Floor
New York, New York 10022
United States of America
(c)
Citizenship:
Armistice Capital, LLC – Delaware
Armistice Capital Master Fund Ltd. – Cayman Islands
Steven Boyd – United States of America
(d).
Title of Class of Securities:
Common Stock
(e).
CUSIP Number:
67001K202

Follow Novelion Therapeutics Inc. (NASDAQ:NVLN)

Page 5 of 10